Aurobindo Pharma
- Market cap
- ₹ 90,294 Cr.
- P/E
- 25x
- P/B
- 2.47x
- 52-week range
- 1,081.4 – 1,740
- ROE
- 10%
- ROCE
- 13%
- Dividend yield
- 0%
- Debt / equity
- 0.21
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Aurobindo Pharma Limited is an India-based pharmaceutical company. The Company is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, branded pharmaceuticals, generic pharmaceuticals, and related services. Its key therapeutic segments include Central nervous systems (CNS), Antiretrovirals (ARVs), Cardiovascular (CVS), SSP - Orals and Sterile, Anti-infectives, Anti-diabetics and Cephalosporins - Orals. It is engaged in developing a range of oncology, non-oncology prescription formulation, and hormonal products. It is developing topical as well as transdermal products in the dermatology therapeutic segment. It is marketing its products globally in approximately 150 countries. Its subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited, Auro Pharma Inc, Aurobindo Pharma (Malta) Limited, APL Swift Services (Malta) Limited, Aurobindo Pharma Industria Farmaceutica Ltd, and others.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Aurobindo Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)25 against a typical 34: cheaper than most peers (1st = cheapest).80th of 220
- Sales growth+16.3% against a typical +15.6% from a year earlier.96th of 197
- Profit growth+25.2% against a typical +18.9% from a year earlier.76th of 160
- Share price, 3 months+3.4% against a typical −0.5%.76th of 200
- Size₹ 90,294.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).8th of 199
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
High safety
Rated AA+ by India Ratings- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | IND AA+; IND A1+ | Stable | 10 Jun 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 10 Jun 2026 | Reaffirmed | IND AA+ | — | India Ratings | ₹ 6,493 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 4 Nov 2026Upcoming | Financial Results/Dividend | To consider and approve the financial results for the period ended September 30, 2026 and dividend |
| 5 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 21 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 6 Apr 2026 | Buyback | To consider buyback for equity shares |
| 9 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 5 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 4 Aug 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7,219 | 7,352 | 7,580 | 7,567 | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 |
| Expenses | 5,846 | 5,753 | 5,920 | 5,949 | 6,230 | 6,401 | 6,622 | 6,265 | 6,608 | 6,873 | 7,103 | 7,271 |
| Operating Profit | 1,373 | 1,599 | 1,660 | 1,618 | 1,566 | 1,578 | 1,760 | 1,603 | 1,678 | 1,773 | 1,750 | 1,880 |
| OPM % | 19% | 22% | 22% | 21% | 20% | 20% | 21% | 20% | 20% | 21% | 20% | 21% |
| Other Income | 188 | 163 | 14 | 221 | 136 | 159 | 135 | 107 | 122 | 123 | 117 | 224 |
| Interest | 68 | 76 | 89 | 111 | 113 | 118 | 115 | 98 | 95 | 93 | 98 | 102 |
| Depreciation | 418 | 423 | 354 | 404 | 382 | 419 | 444 | 406 | 429 | 465 | 479 | 487 |
| Profit before tax | 1,076 | 1,262 | 1,230 | 1,324 | 1,207 | 1,200 | 1,335 | 1,207 | 1,276 | 1,339 | 1,291 | 1,515 |
| Tax % | 30% | 26% | 26% | 31% | 32% | 30% | 32% | 32% | 34% | 32% | 29% | 32% |
| Net Profit | 752 | 940 | 907 | 918 | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 |
| EPS in Rs | 12.92 | 15.98 | 15.51 | 15.69 | 14.07 | 14.56 | 15.56 | 14.2 | 14.61 | 15.67 | 15.86 | 17.78 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 9%
- 5 Years
- 6%
- 3 Years
- 11%
- TTM
- 9%
- 10 Years
- 6%
- 5 Years
- 1%
- 3 Years
- 23%
- TTM
- 11%
- 10 Years
- 8%
- 5 Years
- 19%
- 3 Years
- 24%
- TTM
- —
- 10 Years
- 14%
- 5 Years
- 10%
- 3 Years
- 11%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Aurobindo Pharma | ₹ 1,644.80 | ₹ 90,294 Cr. | 25x | 2.5x | 10% | — |
| Neuland Laboratories | ₹ 18,695.00 | ₹ 23,893 Cr. | 64.3x | 12.6x | 21.4% | 18% |
| Pfizer | ₹ 3,610.35 | ₹ 16,513 Cr. | 27.5x | 5x | 17.2% | 28.7% |
| Unichem Laboratories | ₹ 472.00 | ₹ 3,294 Cr. | 54.3x | 1.5x | 9.8% | 11.5% |
| Jagsonpal Pharmaceuticals | ₹ 213.00 | ₹ 1,402 Cr. | 34.3x | 5.4x | 16.7% | 15% |
| Themis Medicare | ₹ 90.00 | ₹ 826 Cr. | 632.2x | 2.5x | 0.3% | 0.3% |
Management
- Kambam Nithyananda Reddy
- Executive Vice Chairman of the Board, Managing Director, Promoter
- Santhanam Subramanian
- Chief Financial Officer
- Baddigam Adi Reddy
- Compliance Officer, Company Secretary
- Mettu Madan Mohan Reddy
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.